Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Shionogi & Co (4507 JP): Decent 9MFY26 Result; No Revision in FY Forecast; Accelerate Growth Ahead

Shionogi & Co (4507 JP): FY26 Result Falls Short of Expectation; Mixed Guidance for FY27

Shionogi & Co (4507 JP): Strong Start to FY27 as Business Diversification Is Yielding Result

Shionogi & Co (4507 JP): Change Of Gears Likely From FY26, Torii Acquisition Augurs Well

Shionogi & Co (4507 JP): High on HIV Royalty; FY Guidance Reaffirmed; New Launches to Drive Growth

Shionogi & Co (4507 JP): Muted 1H Result; Solid HIV Business Leads FY Profit Guidance Raise

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/shionogi-co-ltd" target="_blank" data-smartkarma-citation="entities:19535:1" rel="noopener">Shionogi &amp; Co (4507 JP)</a> is acquiring rare neurodegenerative disease drug Radicava for $2.5B. The transaction is expected to be immediately accretive in FY27, adding ~$700M in annual global sales.</li>
<li>This acquisition will solidify Shionogi’s strategic focus in rare disease and immediately establish a strong rare disease commercial platform in the U.S. market.</li>
<li>Shionogi has received approval in Japan for inlicensed drug Zurzuvae for the indication of depression and depressive state.</li>
</ul>



Shionogi &amp; Co (4507 JP) is acquiring rare neurodegenerative disease drug Radicava for $2.5B. The transaction is expected to be immediately accretive in FY27, adding ~$700M in annual global sales.
This acquisition will solidify Shionogi’s strategic focus in rare disease and immediately establish a strong rare disease commercial platform in the U.S. market.
Shionogi has received approval in Japan for inlicensed drug Zurzuvae for the indication of depression and depressive state.


Shionogi (4507 JP): $2.5B ALS Drug Buyout and New Approval To Accelerate Portfolio Diversification